What the Study Found
- No single rattlesnake serum protein stopped the venom killing mice; the best of them saved two of five animals.
- A three-protein combination fully protected mice against both western and eastern diamondback rattlesnake venom.
- That mixture’s median effective dose was 5.6 mg/kg against 52.6 mg/kg for CroFab antivenom, roughly a tenfold gap.
- Against puff adder venom the proteins gave no protection at all: none of the five treated mice survived.
The assay is about as blunt as biology gets. Mix 1.5 micrograms of western diamondback venom with a protein you reckon might block it, inject the lot under a mouse’s skin, wait 24 hours, then take the skin off and photograph the bruise. Sean Carroll‘s lab at the University of Maryland had every reason to expect a small bruise, or none at all, because the protein under test came from a family called FETUA (after fetuin-A, the everyday blood protein they all descend from), and this one, FETUA-3, had shut down the venom’s collagen-chewing enzymes in a dish back in 2022. The bruise came back 66 percent bigger than venom alone.
That backwards result is the hinge of a paper published today in the Proceedings of the National Academy of Sciences, and it is the reason the study is a good deal more interesting than the press release announcing it. Carroll’s team was not designing a drug so much as reverse-engineering one, because vipers are notoriously hard to kill with their own venom, and the proteins circulating in their blood that make them that way have been eyed as antivenom material since long before anyone knew what those proteins actually were.
Snakebite affects at least 1.7 million people a year and kills roughly 100,000. Hardly a niche problem. Treatment has barely changed in more than a century: immunize a horse or a sheep with whole venom, harvest the antibodies, then hope the batch is potent enough, that the hospital can shell out for enough vials, and that the patient does not react badly to a large dose of foreign protein. What actually does the damage in a viper bite is a family of enzymes called metalloproteinases, which make up about half the protein in western diamondback venom by weight and shred the scaffolding of blood vessels and connective tissue; they may also open the road for other toxins to spread. Rattlesnakes carry five related blood proteins, FETUA-1 through FETUA-5, that evolved out of an ordinary vertebrate serum protein and became inhibitors of exactly those enzymes.
The Bruises Told Half the Story
So the team ran the same crude assay across all five, and the answer came out close to the reverse of what anyone had predicted. FETUA-2 blocked the bleeding completely, 100 percent inhibition with no variation across the group, FETUA-5 managed 92 percent, and FETUA-1 and FETUA-4 behaved like FETUA-3 and made the bruising worse (the mechanism for that is not understood, and the authors say so).
Blocking hemorrhage is not the same as blocking death, though. In a lethality assay, mice given three times the lethal dose of western diamondback venom premixed with 100 micrograms of a single protein fared poorly whichever protein it was: FETUA-2 saved two of five animals, both of them visibly envenomated, at a significance level sitting just the wrong side of conventional. FETUA-3 saved none.
Then the two were mixed together, and every mouse lived, showing no overt symptoms at all. The protein that did nothing on its own and the protein that made bruising worse turn out to cover each other’s blind spots, which is a tidy piece of evolutionary logic and also the first demonstration, in any pit viper venom, that shutting down metalloproteinases alone is enough to keep an animal alive.
How much protein does that take? Running a dose-response against the same venom put the median effective dose of the three-protein mixture at 5.6 milligrams per kilogram. CroFab, the affinity-purified ovine antivenom that is the North American standard, came in at 52.6. That is the tenfold advantage the release leads with, though on a per molecule basis it falls to seven times, and the CroFab estimate carries an error bar of plus or minus 41.5, nearly as wide as the figure it qualifies.
Worth holding lightly, then. The direction is not really in doubt: whole unfractionated rattlesnake serum also outperformed the commercial product, at 17.1, which is roughly where you would expect a crude mixture of the right ingredients to land.
One Venom Shrugged It Off
Polyvalency, the ability to cover the range of species a clinic might see, is where antivenom design usually founders, and the FETUAs are not exempt. The pair that fully protected mice against western diamondback venom did nothing against the eastern diamondback, a cousin perhaps 7 million years removed; that venom needed all three proteins before every mouse lived.
Push further out and the picture gets patchier. The rattlesnake proteins fully protected mice against Malayan pit viper venom and partly against the Chinese hundred-pace viper, both around 34 million years diverged, and gave partial protection against saw-scaled viper venom. Against Bitis arietans, the puff adder, arguably the most medically important snake in sub-Saharan Africa, they did nothing whatsoever: none of the five treated mice survived, precisely matching the untreated controls, even though the same proteins had inhibited over 95% of that venom’s collagenase activity in a test tube. The press release, which describes broad protection against venoms from multiple viper species separated by millions of years of evolution, does not mention the puff adder.
Carroll frames the programme as borrowing rather than inventing. “This is one of those great stories when nature has already solved a problem we’ve been grappling with for decades,” he says. On the question of which proteins belong in which mixture, and there are a great many possible mixtures, he is content to leave it open: “The ingredients are there.”
The release calls all this an antidote. That word is doing work it has not yet earned, because in every experiment here the venom and the inhibitor were mixed in a tube and incubated for 30 minutes at 37 degrees before anything was injected into anything. Nobody has yet envenomated a mouse and then tried to save it. The authors are straightforward about this, listing rescue experiments among the open questions alongside safety, pharmacokinetics, and what to do about the phospholipase toxins the FETUAs do not touch at all.
What the paper establishes is narrower than the headline and more interesting than it sounds: that a handful of recombinant proteins, brewed in a lab rather than harvested from an immunized animal, can be sufficient to stop a hemorrhagic venom killing a mouse. Whether that scales into something a rural clinic can keep in a fridge is a different question entirely, and the puff adder result is a fair warning about how the answer might go.
- Study type: Experimental preclinical study in mice, with in vitro enzyme assays and comparative genome annotation; peer-reviewed, published in Proceedings of the National Academy of Sciences (Contributed track, reviewers named on the paper).
- Sample size: Groups of four mice for hemorrhage assays and five for lethality assays, with some control groups pooled to ten; BALB/c, male and female, 18–20 g. Six viperid venoms tested in vivo, drawn from pools of up to 100 snakes.
- Intervention: Recombinant Crotalus atrox serum proteins FETUA-1 to FETUA-5, singly and in combination, preincubated with venom for 30 minutes at 37 °C before intraperitoneal or subcutaneous injection.
- Comparator: Venom preincubated with saline. For potency, CroFab affinity-purified ovine antivenom and whole unfractionated C. atrox serum, compared as median effective dose against three times the median lethal dose of C. atrox venom.
- Observation window: 48 hours for lethality and survival scoring; 24 hours for measurement of hemorrhagic lesions.
- Funding / conflicts of interest: Howard Hughes Medical Institute, an endowed chair at the University of Maryland, and Viper Resource Center grant P40OD01960-22. Two authors, including the senior author, are co-inventors on pending patents assigned to the University of Maryland.
- Data availability: fetua gene sequences deposited on Figshare (doi 10.6084/m9.figshare.32189895).
- Main limitation: Author-stated. Every in vivo result comes from preincubating inhibitor with venom before injection; the proteins were never administered after envenomation, so rescue efficacy is untested. The authors also note that blocking metalloproteinases alone will not neutralize all viperid venoms.
Reference
Carroll, S. B., Ukken, F. P., Ayinuola, Y. A., Escalona, L., Suntravat, M., & Sanchez, E. E. (2026). Nature’s antivenom: Combinations of conserved rattlesnake serum metalloproteinase inhibitors block the lethal action of viper venoms. Proceedings of the National Academy of Sciences, 123(32). https://doi.org/10.1073/pnas.2612168123
Frequently Asked Questions
Does this mean a new snakebite treatment is on the way?
A new snakebite treatment is not on the way yet, and the study does not claim one is. Every experiment mixed the venom and the rattlesnake proteins together in a tube before injecting the combination into a mouse, so nobody has yet tested whether the proteins can save an animal that has already been bitten. The authors list those rescue experiments, along with safety and pharmacokinetics work, among the things still to be done.
How can a protein that makes bleeding worse be useful in an antivenom?
A protein that makes bleeding worse can still be useful because viper venom does its damage through many different enzymes, not one. FETUA-3 increased bruising in mice while blocking a separate set of venom enzymes that FETUA-2 leaves alone, so the two together covered a wider spread of targets than either did by itself. Neither protein on its own kept mice alive; the pair did.
Why is viper venom so hard to treat in the first place?
Viper venom is hard to treat because it is not a single poison but a mixture of enzymes, and the mixture differs from species to species. Conventional antivenom is made by immunizing a horse or a sheep with whole venom and harvesting the antibodies, which produces a preparation that is expensive, variable in potency, and mostly made of protein that does nothing useful. Matching one product to the range of snakes a clinic might see is the persistent problem in the field.
Is it true that the rattlesnake proteins worked against every venom tested?
It is not true that the rattlesnake proteins worked against every venom tested. They fully protected mice against three viper venoms and partly against two more, but against puff adder venom they gave no protection at all, with none of the treated mice surviving. That failure came despite the same proteins blocking more than 95% of that venom’s enzyme activity in a test tube.
Cite This Page